Anti-Hypertensive Drugs - Bosnia and Herzegovina

Bosnia and Herzegovina

The revenue of the Anti-Hypertensive Drugs market in Bosnia and Herzegovina is estimated to reach US$3.12m by the year 2024.
It is anticipated that the revenue will witness an annual growth rate (CAGR 2024-2028) of -0.16%, leading to a market volume of US$3.10m by 2028.
When compared globally, United States is expected to generate the highest revenue of US$12,290.00m in 2024.
The demand for anti-hypertensive drugs in Bosnia and Herzegovina is steadily increasing due to the high prevalence of hypertension in the country.

Key regions: Germany, United States, France, China, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Hypertensive Drugs market in Bosnia and Herzegovina has been experiencing significant growth over the past few years.

Customer preferences: Bosnia and Herzegovina has an aging population, which has led to an increase in hypertension cases. This has resulted in a higher demand for anti-hypertensive drugs in the country. Additionally, there has been an increase in awareness about hypertension and its associated risks, which has led to an increase in demand for drugs to manage the condition.

Trends in the market: The Anti-Hypertensive Drugs market in Bosnia and Herzegovina has been growing steadily, with an increasing number of players entering the market. This has led to increased competition, which has resulted in lower prices for consumers. Additionally, there has been a trend towards the use of combination therapies, which has led to an increase in demand for drugs that can treat multiple conditions at once.

Local special circumstances: Bosnia and Herzegovina has a complex healthcare system, which can make it difficult for patients to access the drugs they need. There is also a lack of funding for healthcare, which can make it difficult for patients to afford the drugs they need. Additionally, there is a high level of corruption in the healthcare system, which can make it difficult for patients to access quality care.

Underlying macroeconomic factors: Bosnia and Herzegovina is a developing country, with a relatively low GDP per capita. This means that many people in the country may not be able to afford the drugs they need, which can limit the growth of the Anti-Hypertensive Drugs market. Additionally, there are political and economic uncertainties in the country, which can make it difficult for companies to invest in the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.